{"filings":[{"id":94571,"accession_number":"0001193125-26-211921","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.","Cash, cash equivalents and marketable securities of $452.4M as of March 31, 2026; runway into first half of 2029.","Phase 1 data update for ELVN-001 expected mid-2026; Phase 3 ENABLE-2 initiation expected H2 2026.","ELVN-001 is a potentially best-in-class ATP-competitive BCR::ABL inhibitor for CML."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107053,"accession_number":"0001193125-26-088195","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.","Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.","Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.","Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.","Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107052,"accession_number":"0001193125-26-005535","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.","Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.","Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.","Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123393,"accession_number":"0001193125-25-315196","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Fair appointed President, CEO and board member, effective December 11, 2025.","Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.","Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.","Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.","Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123391,"accession_number":"0001193125-25-278466","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.","Cash, equivalents and marketable securities of $477.6M at Sep 30, 2025, expected to fund operations into first half 2029.","Net loss of $20.1M for Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M, G&A $6.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123392,"accession_number":"0001193125-25-277580","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.","Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.","Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.","On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.","Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140055,"accession_number":"0001193125-25-179837","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.","Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.","Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.","Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.","Recent public offering generated $230M gross proceeds, strengthening balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157703,"accession_number":"0001193125-25-146874","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Enliven Therapeutics stockholders elect three Class II directors, ratify Deloitte as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).","Ratified Deloitte & Touche LLP as independent auditor for FY2025 (45,392,647 for, 2,435 against, 35,215 abstain).","Broker non-votes of 8,099,804 existed for director elections; ratification had no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157702,"accession_number":"0001193125-25-141085","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.","Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.","Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.","Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157701,"accession_number":"0001193125-25-140285","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.","90 patients enrolled; 80% remain on study with median treatment duration ~29 weeks; heavily pretreated (67% received ≥3 prior TKIs).","Safety: only 3.4% dose reductions, 4.6% discontinuations due to AEs; no treatment-related arterial occlusive events; no MTD reached.","PK supports once-daily dosing with food flexibility and low drug-drug interaction potential.","Company expects to initiate first head-to-head Phase 3 pivotal trial in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157700,"accession_number":"0000950170-25-071387","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.","Cash, equivalents and marketable securities $289.6M; runway into late 2027.","ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.","Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.","Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176071,"accession_number":"0000950170-25-038737","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).","Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.","R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).","ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.","First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192985,"accession_number":"0000950170-24-126323","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $291.8M as of Sept 30, 2024; runway into late 2026.","Net loss $23.2M (Q3 2024) vs $20.8M (Q3 2023); R&D expenses $21.3M.","ELVN-001 Phase 1: cumulative MMR 44% (8/18) by 24 weeks; no dose reductions at ≥40 mg due to TRAEs.","Plan to report additional ELVN-001 data in 2025 with ~60-100 patients across lines of therapy.","ELVN-002 trials in HER2+ MBC and CRC ongoing; data anticipated in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209358,"accession_number":"0000950170-24-096204","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.","Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).","ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.","ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.","Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227353,"accession_number":"0001193125-24-163507","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.","Certificate of Incorporation amended to limit officer liability for monetary damages under Delaware law.","Class I directors Mika Derynck (36.4M for) and Rishi Gupta (37.4M for) elected to 2027 annual meeting.","Deloitte & Touche LLP ratified as independent auditor for FY 2024 with 42.9M votes for.","All proposals passed; broker non-votes 4.6M on director elections and other items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227349,"accession_number":"0001193125-24-149141","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K/A","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.","Her board appointment was reported April 9, 2024; committee role now determined.","Appointment follows recommendation of the Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227352,"accession_number":"0000950170-24-059544","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.","ELVN-001 Phase 1 proof-of-concept: 44% (7/16) cumulative MMR rate by week 12 in response-evaluable CML patients.","Entered $90M PIPE financing from new/existing investors; expected cash runway into late 2026.","Appointed Dr. Lori Kunkel to Board of Directors.","Activated first site for ELVN-002 combo trial with trastuzumab in HER2+ cancers; first dosing expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227351,"accession_number":"0001193125-24-092522","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.","No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.","ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.","89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.","Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227350,"accession_number":"0001193125-24-090821","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.","Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.","No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.","Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246222,"accession_number":"0001193125-24-070839","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.","PIPE priced at ~11% premium to March 18 close; expected to close March 21, 2024.","Proceeds plus existing cash expected to fund operations into late 2026 and through key clinical milestones.","ELVN-001 Phase 1a proof-of-concept data to be presented at KOL event on April 11, 2024.","ELVN-002 combination trial first patient dosing expected in Q2 2024; Phase 1 data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246221,"accession_number":"0000950170-24-031482","cik":1672619,"company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.","Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.","Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).","ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2489794158.066168,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}